• Harkness E, Macdonald W, Valderas J, Coventry P, Gask L, Bower P. Identifying Psychosocial Interventions That Improve Both Physical and Mental Health in Patients With Diabetes: A systematic review and meta-analysis. Diabetes Care. 2010 Apr;33(4):926-30.

  • Frias JP, Lim CG, Ellison JM, Montandon CM. Review of Adverse Events Associated With False Glucose Readings Measured by GDH-PQQ-Based Glucose Test Strips in the Presence of Interfering Sugars. Diabetes Care. 2010 Apr;33(4):728-9.

  • Yamamoto M, Yamaguchi T, Yamauchi M, Sugimoto T. Low Serum Level of the Endogenous Secretory Receptor for Advanced Glycation End Products (esRAGE) Is a Risk Factor for Prevalent Vertebral Fractures Independent of Bone Mineral Density in Patients with Type 2 Diabetes: Response to Yamagishi. Diabetes Care. 2010 Apr;33(4):e59.

  • Yamagishi S. Low Serum Level of the Endogenous Secretory Receptor for Advanced Glycation End Products (esRAGE) Is a Risk Factor for Prevalent Vertebral Fractures Independent of Bone Mineral Density in Patients With Type 2 Diabetes: Response to Yamamoto et al. Diabetes Care. 2010 Apr;33(4):e58.

  • Davidson MB. Correction to the 2010 report on the diagnosis and classification of diabetes. Diabetes Care. 2010 Apr;33(4):e57.

  • Eraso LH, Reilly MP. Association of lower plasma fetuin-a levels with peripheral arterial disease in type 2 diabetes: response to stefan et Al. Diabetes Care. 2010 Apr;33(4):e56.

  • Stefan N, Weikert C, Ix JH, Fritsche A, Häring HU. Association of lower plasma fetuin-a levels with peripheral arterial disease in type 2 diabetes: response to eraso et Al. Diabetes Care. 2010 Apr;33(4):e55.

  • Bloomgarden ZT. Cardiovascular disease in diabetes. Diabetes Care. 2010 Apr;33(4):e49-54.

  • Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, Trautmann M. Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Prediabetes. Diabetes Care. 2010 Mar 23.

  • Raman VS, Mason KJ, Rodriguez LM, Hassan K, Yu X, Bomgaars L, Heptulla RA. The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes. Diabetes Care. 2010 Mar 23.

  • Ficociello LH, Rosolowsky ET, Niewczas MA, Maselli NJ, Weinberg JM, Aschengrau A, Eckfeldt JH, Stanton RC, Galecki AT, Doria A, Warram JH, Krolewski AS. High-Normal Serum Uric Acid Increases Risk of Early Declining Renal Function In Type 1 Diabetes: Results of 6-year Follow-up. Diabetes Care. 2010 Mar 23.

  • Castle JR, Engle JM, El Youssef J, Massoud RG, Yuen KC, Kagan R, Ward WK. Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes. Diabetes Care. 2010 Mar 23.

  • Liu B, Jorm L, Banks E. PARITY, BREASTFEEDING AND THE SUBSEQUENT RISK OF MATERNAL TYPE 2 DIABETES. Diabetes Care. 2010 Mar 23.

  • The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The Cost-Effectiveness of Continuous Glucose Monitoring in Type 1 Diabetes. Diabetes Care. 2010 Mar 23.

  • Redmon JB, Bertoni AG, Connelly S, Fenney PA, Glasser S, Glick H, Greenway F, Hesson LA, Lawlor MS, Montez M, Montgomery B. Effect of the Look AHEAD Study Intervention on Medication Use and Related Cost to Treat Cardiovascular Disease Risk Factors in Individuals with Type 2 Diabetes. Diabetes Care. 2010 Mar 23.

  • Gaziano JM, Cincotta AH, O'Connor CM, Ezrokhi M, Rutty D, Ma ZJ, Scranton RE. Randomized Clinical Trial of Quick Release-Bromocriptine among Patients with Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes. Diabetes Care. 2010 Mar 23.

  • Buse JB, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, Blonde L, Rosenstock J; for the Liraglutide Effect and Action in Diabetes (LEAD)-6 Study Group. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010 Mar 23.

  • Research & Development

    Research & Development

     

    Our product development team continues its strong research orientation in formulation development to transform BPL into a truly international one.

     Read More

    Manufacturing Facilities

    Manufacturing Facilities

     

    Beximco Pharmaceuticals Ltd. (Beximco Pharma) is a leading manufacturer of medicines and active pharmaceutical ingredients (APIs) based in Bangladesh.

     Read More

    Corporate Responsibility

    Corporate Social Responsibility

     

    CSR initiatives are an integral part of our strategic commitment, and we are always guided by strong ethical values to operate responsibly within broader social and economic context.

     Read More

    Health & Wellness

    Health & Wellness

     

    Life's all about staying healthy and enjoying the good things in life! However, illness is inevitable at all stages of life. In this area learn about the common health problems.

     Read More

    Our Product

    • All
    • Allergic Disorders
    • Analgesics & Antipyretic
    • Anti–infectives
    • Cardiovascular
    • Central Nervous System
    • Cough & Cold
    • Endocrine & Diabetes
    • Eye Care
    • Gastrointestinal
    • Hormones & Steroid
    • Intravenous Fluids
    • Muscloskeletal
    • Oncology
    • Other Products
    • Respiratory
    • Skin Care
    • Vitamins & Minerals Supplement
    load more hold SHIFT key to load all

    Global Footprint

    Beximco Pharma has so far exported medicines to more than 40 countries around the world.

     Read More

    Contract Manufacturing Opportunities

    Rising cost of healthcare and medicines has become a global concern, and in order to reduce cost across the value chain, pharmaceutical companies from developed markets.

     Read More

    Our People

    We believe, our dedicated and highly skilled people – their collective resolve to excel- have always guided us towards newer achievements and set a course for the bright future.

     Read More

    Investor Relations

    This section of our website contains essential information on Beximco Pharmaceuticals Ltd. You can view and download our financial reports and keep up to-date with the latest news and company information.

     Read More

    Winner

    • invima
    • Asaia most promising brand

     

     

    • FDA Export

    Certified

    • TGA
    • AGES
    • GCC
    • TFDA
    • ANVISA
    • Health Canada